Posted 13 hours ago

On late Friday, it was announced that Lev Pharmaceuticals' (LEVP.OB) prophylactic treatment for the rare but life-threatening disorder known as hereditary angioedema- HAE was approved by the FDA.This

Posted 13 hours ago

It was a tumultuous week in the markets, with US indexes losing between 15% and 18%. Shanghai was also negative, after its week of vacation, dropping 15%. By comparison, the CBT Index, an index comp

Tags: biotech

Posted 2 days ago

I could easily blog about how badly biopharma is performing in this bear market, how all of the big pharma stocks hit new lows this morning with the lone exception of AstraZeneca (Update: AstraZeneca

Tags: biotech pharma

Posted 2 days ago

History has shown again and again that times like these represent a huge long-term buying opportunity. This may be particularly true for the biotech segment that, despite weathering the storm better t

Tags: biotech

Posted 2 days ago

Merck & Co. v. Apotex, No. 2008-1133 (Fed. Cir. 2008) In 2005, Hi-Tech Pharmacal (HITK) became the first company to file a paragraph IV certification relating to Merck's (MRK) glaucoma drugs Trusopt a

Posted 3 days ago

Lev Pharmaceuticals (LEVP.OB) is a biotechnology company, which has focused on developing a treatment for the serious, and potentially life-threatening disorder known as hereditary angioedema, which h

Tags: biotech biotechnology

Posted 5 days ago

Typical of the irony in this market, after buying a large swath of Sequenom (SQNM) Monday at $21, in after hours comes news of competition (i.e. a study of 18 patients). Details found here.Research

Tags: genetic health

Posted 5 days ago

Recent gyrations in the market have caused more than one investor some heartburn. Each day I hear disgruntled comments due to losses and see many people looking for an out.Ryan Detrick, senior technic

Posted 5 days ago

Well, it looks as if I'll finally be able to stop talking about Imclone (IMCL): the word came out Monday morning that they've agreed to a $70/share deal with Lilly (LLY). Some thoughts on this:1. I wo

Posted 5 days ago

Although the third quarter of this year was one of the more downbeat ones, there are still some ETFs that managed to post gains amid the wreckage.Doug Rogers for Investor s Business Daily reports th

Tags: biotech